FDA Approves RAS Mutation Detection Kit as Companion Diagnostic for Panitumumab in mCRC

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement from EntroGen.

Related Keywords

Matthew Minkovsky ,Amgen ,Detection Kit ,Dmcrc ,Fda ,Colorectal ,